Artwork

Content provided by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

MDMA and Post Traumatic Stress Disorder: The Fight for Psychedelic Therapy

51:20
 
Share
 

Manage episode 424185118 series 3402892
Content provided by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We hear a powerful story about the power of MDMA to help heal PTSD.
An FDA advisory committee recently voted against approval of MDMA as a treatment for Post Traumatic Stress Disorder (PTSD), despite extremely promising results from clinical trials. So, in this episode, Molly speaks with Cristina Pearse, founder and CEO of the Protea Foundation, who received MDMA treatment as part of the recent trials. Cristina describes the impact of her childhood trauma as a powerful tsunami. With the help of MDMA-assisted therapy, she says, it became just a puddle at her feet.

Together, we discuss the potential of this medicine, the FDA study design, the recent vote, and the role of advocacy in securing access to this life saving medicine.

If you enjoy Ketamine Insights, please share it with a friend and rate or review it on your favorite podcast platform. Online engagement (ie. ratings and reviews) helps us reach a larger audience.

A New York Times article about the FDA vote on MDMA, which took place on June 4, 2024: https://www.nytimes.com/2024/06/04/health/fda-mdma-therapy-ptsd.html
You can read (MDMA applicant) Lykos' response to the vote here: https://news.lykospbc.com/2024-06-13-Lykos-Therapeutics-Statement-on-FDA-Advisory-Committee-Meeting
Support us and join our community at https://www.patreon.com/ketamineinsights
or at https://mollydunn.substack.com/

Email us at ketamineinsights@gmail.com (we love to hear from you!)

You can also find all of our episodes on YouTube and our website https://ketamineinsights.com/

If you or someone you know is experiencing a mental health crisis, please get help. In the US, you can dial 988. You are never all alone.

As always: Remember to advocate for yourself, and never ration your joy.

Support the Show.

  continue reading

Chapters

1. Introduction to Ketamine Insights (00:00:00)

2. FDA's Advisory Committee Vote on MDMA (00:00:47)

3. Understanding the MDMA Study (00:02:17)

4. Concerns Raised by the FDA Advisory Committee (00:03:26)

5. Personal Reflections on PTSD and Treatment (00:04:37)

6. Interview with Cristina Pearse (00:05:22)

7. Cristina's Experience with PTSD (00:05:47)

8. The Impact of Therapy and MDMA (00:08:37)

9. Challenges in the FDA Approval Process (00:12:56)

10. The Future of MDMA Theraoy (00:24:00)

11. The Hidden Impact of Unreported Trauma (00:27:55)

12. The Role of Trauma in Treatment-Resistant Depression (00:28:49)

13. The Potential of MDMA-Assisted Therapy (00:29:56)

14. The Importance of Addressing Trauma Holistically (00:32:33)

15. The Need for Trauma Education and Qualified Therapists (00:45:05)

16. Conclusion: Advocacy and Call to Action (00:46:42)

19 episodes

Artwork
iconShare
 
Manage episode 424185118 series 3402892
Content provided by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Molly Dunn & Lynn Schneider, Molly Dunn, and Lynn Schneider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We hear a powerful story about the power of MDMA to help heal PTSD.
An FDA advisory committee recently voted against approval of MDMA as a treatment for Post Traumatic Stress Disorder (PTSD), despite extremely promising results from clinical trials. So, in this episode, Molly speaks with Cristina Pearse, founder and CEO of the Protea Foundation, who received MDMA treatment as part of the recent trials. Cristina describes the impact of her childhood trauma as a powerful tsunami. With the help of MDMA-assisted therapy, she says, it became just a puddle at her feet.

Together, we discuss the potential of this medicine, the FDA study design, the recent vote, and the role of advocacy in securing access to this life saving medicine.

If you enjoy Ketamine Insights, please share it with a friend and rate or review it on your favorite podcast platform. Online engagement (ie. ratings and reviews) helps us reach a larger audience.

A New York Times article about the FDA vote on MDMA, which took place on June 4, 2024: https://www.nytimes.com/2024/06/04/health/fda-mdma-therapy-ptsd.html
You can read (MDMA applicant) Lykos' response to the vote here: https://news.lykospbc.com/2024-06-13-Lykos-Therapeutics-Statement-on-FDA-Advisory-Committee-Meeting
Support us and join our community at https://www.patreon.com/ketamineinsights
or at https://mollydunn.substack.com/

Email us at ketamineinsights@gmail.com (we love to hear from you!)

You can also find all of our episodes on YouTube and our website https://ketamineinsights.com/

If you or someone you know is experiencing a mental health crisis, please get help. In the US, you can dial 988. You are never all alone.

As always: Remember to advocate for yourself, and never ration your joy.

Support the Show.

  continue reading

Chapters

1. Introduction to Ketamine Insights (00:00:00)

2. FDA's Advisory Committee Vote on MDMA (00:00:47)

3. Understanding the MDMA Study (00:02:17)

4. Concerns Raised by the FDA Advisory Committee (00:03:26)

5. Personal Reflections on PTSD and Treatment (00:04:37)

6. Interview with Cristina Pearse (00:05:22)

7. Cristina's Experience with PTSD (00:05:47)

8. The Impact of Therapy and MDMA (00:08:37)

9. Challenges in the FDA Approval Process (00:12:56)

10. The Future of MDMA Theraoy (00:24:00)

11. The Hidden Impact of Unreported Trauma (00:27:55)

12. The Role of Trauma in Treatment-Resistant Depression (00:28:49)

13. The Potential of MDMA-Assisted Therapy (00:29:56)

14. The Importance of Addressing Trauma Holistically (00:32:33)

15. The Need for Trauma Education and Qualified Therapists (00:45:05)

16. Conclusion: Advocacy and Call to Action (00:46:42)

19 episodes

すべてのエピソード

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide